IN2014CN00510A - - Google Patents
Info
- Publication number
- IN2014CN00510A IN2014CN00510A IN510CHN2014A IN2014CN00510A IN 2014CN00510 A IN2014CN00510 A IN 2014CN00510A IN 510CHN2014 A IN510CHN2014 A IN 510CHN2014A IN 2014CN00510 A IN2014CN00510 A IN 2014CN00510A
- Authority
- IN
- India
- Prior art keywords
- peptides
- pcb
- relates
- owing
- phycocyanobilin
- Prior art date
Links
- NNMALANKTSRILL-ZUTFDUMMSA-N 3-[(2z,5z)-2-[[3-(2-carboxyethyl)-5-[(z)-[(3z,4r)-3-ethylidene-4-methyl-5-oxopyrrolidin-2-ylidene]methyl]-4-methyl-1h-pyrrol-2-yl]methylidene]-5-[(4-ethyl-3-methyl-5-oxopyrrol-2-yl)methylidene]-4-methylpyrrol-3-yl]propanoic acid Chemical compound O=C1C(CC)=C(C)C(\C=C/2C(=C(CCC(O)=O)C(=C/C3=C(C(C)=C(\C=C/4\C(\[C@@H](C)C(=O)N\4)=C/C)N3)CCC(O)=O)/N\2)C)=N1 NNMALANKTSRILL-ZUTFDUMMSA-N 0.000 abstract 4
- INPDFIMLLXXDOQ-UHFFFAOYSA-N Phycocyanobilin Natural products CCC1=C(C)C(=CC2=NC(=C/c3[nH]c(C=C/4C(C(C(N4)=O)C)=CC)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O INPDFIMLLXXDOQ-UHFFFAOYSA-N 0.000 abstract 4
- 108010072011 phycocyanobilin Proteins 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2011000146A CU23963B1 (es) | 2011-07-01 | 2011-07-01 | Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas |
| PCT/CU2012/000003 WO2013004203A1 (es) | 2011-07-01 | 2012-06-29 | Compuestos y combinaciones farmacéuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00510A true IN2014CN00510A (de) | 2015-04-03 |
Family
ID=46614264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN510CHN2014 IN2014CN00510A (de) | 2011-07-01 | 2012-06-29 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9518085B2 (de) |
| EP (1) | EP2733149B9 (de) |
| JP (1) | JP6023803B2 (de) |
| KR (1) | KR101987978B1 (de) |
| CN (1) | CN103649106B (de) |
| AR (1) | AR087034A1 (de) |
| AU (1) | AU2012280776B2 (de) |
| BR (1) | BR112013033970B1 (de) |
| CA (1) | CA2838496C (de) |
| CU (1) | CU23963B1 (de) |
| DK (1) | DK2733149T3 (de) |
| ES (1) | ES2601887T3 (de) |
| IN (1) | IN2014CN00510A (de) |
| MX (1) | MX345534B (de) |
| RU (1) | RU2569302C2 (de) |
| SI (1) | SI2733149T1 (de) |
| WO (1) | WO2013004203A1 (de) |
| ZA (1) | ZA201309554B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3013355B1 (de) * | 2013-06-25 | 2019-08-07 | ICM - Institut du Cerveau et da la Moelle Epinière | Il-2 zur verwendung in der behandlung von alzheimer-krankheit und verwandten erkrankungen |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| RU2613765C1 (ru) * | 2016-01-26 | 2017-03-21 | Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет им. М.К.Аммосова" | Способ лечения спиноцеребеллярной атаксии |
| CN108752445B (zh) * | 2018-06-20 | 2021-04-30 | 广东药科大学 | 一种螺旋藻蛋白的制备工艺及其神经保护用途 |
| KR102152407B1 (ko) * | 2019-02-26 | 2020-09-07 | (주)나우코스 | 스피루리나에서 유래한 파이코시아노블린 및 이의 유도체를 유효성분으로 포함하는 화장료 조성물 |
| KR20210091664A (ko) | 2020-01-14 | 2021-07-22 | 경북대학교 산학협력단 | 중간엽 줄기세포 유래 단백질을 포함하는 소뇌성운동실조증의 치료 예후를 예측하기 위한 바이오마커, 및 이를 이용한 소뇌성운동실조증의 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5709855A (en) | 1995-09-22 | 1998-01-20 | Bockow; Barry I. | Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain |
| US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| US7025965B1 (en) * | 2003-02-12 | 2006-04-11 | Pharma Chemie, Inc. | Method of use and dosage composition of bluegreen algae extract for inflammation in animals |
| WO2004084933A1 (en) * | 2003-03-28 | 2004-10-07 | Faron Pharmaceuticals Oy | Elevation of adenosine level by cytokine-induced expression of cd73 |
| CU23581A1 (es) * | 2005-10-28 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer |
| US9522167B2 (en) * | 2006-06-27 | 2016-12-20 | Nutratec, s.r.l. | Alphanizomenon flos aquae preparation, extracts and purified components thereof for the treatment of neurological, neurodegenerative and mood disorders |
| CA2668757C (en) * | 2006-11-13 | 2016-08-23 | Mark Fredrick Mccarty | Composition for inhibiting nadph oxidase activity |
-
2011
- 2011-07-01 CU CU2011000146A patent/CU23963B1/es unknown
-
2012
- 2012-06-29 JP JP2014517444A patent/JP6023803B2/ja active Active
- 2012-06-29 SI SI201230756A patent/SI2733149T1/sl unknown
- 2012-06-29 WO PCT/CU2012/000003 patent/WO2013004203A1/es active Application Filing
- 2012-06-29 US US14/127,369 patent/US9518085B2/en active Active
- 2012-06-29 DK DK12743356.3T patent/DK2733149T3/en active
- 2012-06-29 RU RU2014103246/04A patent/RU2569302C2/ru active
- 2012-06-29 KR KR1020147002552A patent/KR101987978B1/ko active IP Right Grant
- 2012-06-29 MX MX2013015206A patent/MX345534B/es active IP Right Grant
- 2012-06-29 EP EP12743356.3A patent/EP2733149B9/de active Active
- 2012-06-29 CN CN201280032375.5A patent/CN103649106B/zh active Active
- 2012-06-29 AU AU2012280776A patent/AU2012280776B2/en active Active
- 2012-06-29 CA CA2838496A patent/CA2838496C/en active Active
- 2012-06-29 ES ES12743356.3T patent/ES2601887T3/es active Active
- 2012-06-29 IN IN510CHN2014 patent/IN2014CN00510A/en unknown
- 2012-06-29 BR BR112013033970-5A patent/BR112013033970B1/pt active IP Right Grant
- 2012-07-02 AR ARP120102397A patent/AR087034A1/es unknown
-
2013
- 2013-12-18 ZA ZA2013/09554A patent/ZA201309554B/en unknown
-
2016
- 2016-11-10 US US15/348,451 patent/US20170119733A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CU20110146A7 (es) | 2013-02-26 |
| CA2838496C (en) | 2020-01-07 |
| CN103649106A (zh) | 2014-03-19 |
| WO2013004203A1 (es) | 2013-01-10 |
| CN103649106B (zh) | 2016-01-20 |
| EP2733149B9 (de) | 2019-05-15 |
| US20140356319A1 (en) | 2014-12-04 |
| AU2012280776A1 (en) | 2014-01-23 |
| CA2838496A1 (en) | 2013-01-10 |
| JP6023803B2 (ja) | 2016-11-09 |
| BR112013033970B1 (pt) | 2022-10-18 |
| US20170119733A1 (en) | 2017-05-04 |
| EP2733149A1 (de) | 2014-05-21 |
| KR20140078601A (ko) | 2014-06-25 |
| BR112013033970A2 (pt) | 2017-02-14 |
| EP2733149B1 (de) | 2016-09-28 |
| RU2569302C2 (ru) | 2015-11-20 |
| AR087034A1 (es) | 2014-02-05 |
| ZA201309554B (en) | 2014-08-27 |
| CU23963B1 (es) | 2013-12-11 |
| ES2601887T3 (es) | 2017-02-16 |
| RU2014103246A (ru) | 2015-08-10 |
| MX2013015206A (es) | 2014-02-20 |
| DK2733149T3 (en) | 2016-11-28 |
| JP2014520764A (ja) | 2014-08-25 |
| MX345534B (es) | 2017-02-03 |
| SI2733149T1 (sl) | 2017-01-31 |
| KR101987978B1 (ko) | 2019-06-11 |
| AU2012280776B2 (en) | 2016-07-14 |
| US9518085B2 (en) | 2016-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| EP3386484A4 (de) | Zusammensetzungen und verfahren zur abgabe von therapeutischen wirkstoffen | |
| WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
| MX2017007641A (es) | Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas. | |
| HK1247957A1 (zh) | T細胞輸送治療分子的組合物和方法 | |
| IN2014DN10386A (de) | ||
| PH12015500983A1 (en) | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| IN2014MN01736A (de) | ||
| PH12021551189A1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| MX2014004766A (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
| MX2015016741A (es) | Inhibidores de pi3 cinasa delta y gama selectivos duales. | |
| EP3024472A4 (de) | Ophthalmische verwendung von toxinbasierten therapeutischen peptiden und pharmazeutische zusammensetzungen davon | |
| IN2014CN00510A (de) | ||
| MX2015000618A (es) | Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas. | |
| HK1232242A1 (zh) | 用於癌症靶向治療的包含基於重組血紅蛋白蛋白質或亞基的治療劑的藥物組合物 | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| MX2016006544A (es) | Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas. | |
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| EP3362096A4 (de) | Ophthalmische behandlungszusammensetzung und trägerstoff zur freisetzung von pharmazeutischen substanzen oder therapeutika | |
| EP3265108A4 (de) | Peptide und zusammensetzungen damit sowie verwendungen davon bei der behandlung von krankheiten | |
| EP2957569A4 (de) | (argo)n-angiotensin-(1-7)peptid und pharmazeutische zusammensetzungen zur behandlung von erkrankungen |